Patents by Inventor Christophe Bonny

Christophe Bonny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intracellular delivery of biological effectors
    Patent number: 7034109
    Abstract: The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novelpeptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: April 25, 2006
    Inventor: Christophe Bonny
  • Intracellular delivery of biological effectors
    Patent number: 7033597
    Abstract: The invention relates to sequences of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: April 25, 2006
    Assignee: Université de Lausanne
    Inventor: Christophe Bonny
  • Intracellular delivery of biological effectors
    Patent number: 6960648
    Abstract: The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: November 1, 2005
    Assignee: Universite de Lausanne
    Inventor: Christophe Bonny
  • Cell-permeable peptide inhibitors of the jnk signal transduction pathway
    Publication number: 20050106695
    Abstract: The invention provides cell-permeable peptides that selectively block the branch of the JNK signaling pathway controlled by the islet-brain (IB) proteins. The provided cell-permeable peptides block the binding of intermediate kinases in the c-Jun amino terminal kinase (JNK) signaling pathway, thereby decreasing the downstream effects of c-Jun amino terminal kinase (JNK).
    Type: Application
    Filed: January 9, 2003
    Publication date: May 19, 2005
    Inventor: Christophe Bonny
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Publication number: 20050043241
    Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
    Type: Application
    Filed: August 23, 2004
    Publication date: February 24, 2005
    Inventor: Christophe Bonny
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Patent number: 6780970
    Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: August 24, 2004
    Assignee: University of Lausanne
    Inventor: Christophe Bonny
  • Intracellular delivery of biological effectors
    Publication number: 20040110690
    Abstract: The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novelpeptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.
    Type: Application
    Filed: December 4, 2003
    Publication date: June 10, 2004
    Inventor: Christophe Bonny
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Publication number: 20040082509
    Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
    Type: Application
    Filed: June 9, 2003
    Publication date: April 29, 2004
    Inventor: Christophe Bonny
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Publication number: 20030220480
    Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
    Type: Application
    Filed: January 15, 2003
    Publication date: November 27, 2003
    Inventor: Christophe Bonny
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Publication number: 20030175920
    Abstract: The invention provides cell-permeable peptides that selectively block the branch of the JNK signaling pathway controlled by the islet-brain (IB) proteins. The provided cell-permeable peptides block the binding of intermediate kinases in the c-Jun amino terminal kinase (JNK) signaling pathway, thereby decreasing the downstream effects of c-Jun amino terminal kinase (JNK).
    Type: Application
    Filed: January 9, 2003
    Publication date: September 18, 2003
    Inventor: Christophe Bonny
  • Transcription factor islet-brain 1 (IB1)
    Patent number: 6620914
    Abstract: The identification and characterisation of human and rat Islet-Brain 1 (IB1) is disclosed, a transcriptional activator that is involved in the control of the GLUT2 and insulin genes by interacting with homologous cis-regulatory elements of the GLUT2 and insulin promoters. The rat IB1 cDNA encodes a 714 amino acid protein and the human IB1 cDNA a 711 amino acid protein. The use of IB1 polypeptides, nucleic acid, agonists and antagonists in the treatment or diagnosis of diabetes, neurological diseases such as dementia and/or parkinsonism, the inhibition/promotion of apoptosis and cancer is disclosed.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: September 16, 2003
    Inventors: Gerard Waeber, Christophe Bonny
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Patent number: 6610820
    Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: August 26, 2003
    Assignee: University of Lausanne
    Inventor: Christophe Bonny
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Publication number: 20030108539
    Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
    Type: Application
    Filed: June 7, 2002
    Publication date: June 12, 2003
    Inventor: Christophe Bonny
  • Intracellular delivery of biological effectors
    Publication number: 20030032594
    Abstract: The invention relates to sequences of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.
    Type: Application
    Filed: June 7, 2002
    Publication date: February 13, 2003
    Inventor: Christophe Bonny
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Publication number: 20020127676
    Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
    Type: Application
    Filed: October 3, 2001
    Publication date: September 12, 2002
    Inventor: Christophe Bonny
  • Intracellular delivery of biological effectors
    Publication number: 20020120100
    Abstract: The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.
    Type: Application
    Filed: October 15, 2001
    Publication date: August 29, 2002
    Inventor: Christophe Bonny
  • Transcription factor Islet-Brain 1 (IB1)
    Patent number: 5880261
    Abstract: Transcriptional activator Islet-Brain 1 (IB1) is disclosed which is involved in the control of the GLUT2 and insulin genes by interacting with homologous cis-regulatory elements of the GLUT2 and insulin promoters, and to materials and methods deriving from this work. In particular, the use of IB1 nucleic acid, IB1 polypeptides and anti-IB1 antibodies in the diagnosis, and prophylactic and therapeutic treatment of conditions such as diabetes and neurological diseases such as dementia and/or parkinsonism is disclosed.
    Type: Grant
    Filed: May 20, 1997
    Date of Patent: March 9, 1999
    Inventors: Gerard Waeber, Christophe Bonny